B
Novo Nordisk A/S NONOF
$123.71 $4.653.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
EPS (TTM)
B
Buy 2/12/2024Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B from B+ on 2/12/2024 due to a noticeable decline in the growth index, total return index and valuation index. Operating cash flow declined 76.95% from $5.98B to $1.38B, and earnings per share declined from $0.7302 to $0.7086.
B
Buy 11/3/2023Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B+ from B on 11/3/2023 due to a large increase in the growth index, valuation index and solvency index. Operating cash flow increased 43.28% from $4.18B to $5.98B, earnings per share increased from $0.6305 to $0.7302, and EBIT increased 12.61% from $3.49B to $3.93B.
B
Buy 1/5/2023Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B from B+ on 1/5/2023 due to a noticeable decline in the total return index and valuation index.
B
Buy 12/21/2022Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B+ from B on 12/21/2022 due to a substantial increase in the total return index.
B
Buy 8/9/2022Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B from B+ on 8/9/2022 due to a large decline in the total return index, dividend index and valuation index.
B
Buy 7/15/2022Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B+ from A- on 7/15/2022 due to a decline in the total return index and valuation index.
A
Buy 6/30/2022Upgraded
Novo Nordisk A/S (NONOF) was upgraded to A- from B on 6/30/2022 due to a major increase in the total return index.
B
Buy 6/24/2022Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B from B+ on 6/24/2022 due to a noticeable decline in the total return index.
B
Buy 6/15/2022Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B+ from A- on 6/15/2022 due to a decline in the total return index, valuation index and dividend index.
A
Buy 5/31/2022Upgraded
Novo Nordisk A/S (NONOF) was upgraded to A- from B+ on 5/31/2022 due to a noticeable increase in the total return index, valuation index and dividend index.
B
Buy 5/10/2022Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B+ from B on 5/10/2022 due to a substantial increase in the total return index and dividend index.
B
Buy 3/25/2022Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B from B+ on 3/25/2022 due to a decline in the volatility index, total return index and valuation index.
B
Buy 2/3/2022Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B+ from B on 2/3/2022 due to a noticeable increase in the valuation index and solvency index.
B
Buy 1/13/2022Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B from A- on 1/13/2022 due to a major decline in the total return index and volatility index.
A
Buy 1/7/2022Upgraded
Novo Nordisk A/S (NONOF) was upgraded to A- from B+ on 1/7/2022 due to an increase in the valuation index.
B
Buy 12/20/2021Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B+ from A- on 12/20/2021 due to a decline in the valuation index.
A
Buy 12/3/2021Upgraded
Novo Nordisk A/S (NONOF) was upgraded to A- from B+ on 12/3/2021 due to an increase in the volatility index, growth index and total return index. Total revenue increased 5.42% from $5.36B to $5.65B, and EBIT increased 0.89% from $2.4B to $2.42B.
B
Buy 10/22/2021Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B+ from B on 10/22/2021 due to a large increase in the total return index and volatility index.
B
Buy 10/21/2021Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B from C on 10/21/2021 due to an increase in the total return index and volatility index.
C
Hold 8/6/2021Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C from B on 8/6/2021 due to a decline in the dividend index and solvency index.
B
Buy 7/16/2021Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B from B+ on 7/16/2021 due to a decline in the valuation index and dividend index.
B
Buy 7/1/2021Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B+ from B on 7/1/2021 due to an increase in the total return index and valuation index.
B
Buy 6/16/2021Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B from B+ on 6/16/2021 due to a decline in the valuation index and dividend index.
B
Buy 5/7/2021Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B+ from B on 5/7/2021 due to a noticeable increase in the volatility index, dividend index and total return index.
B
Buy 2/16/2021Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B from B- on 2/16/2021 due to an increase in the volatility index.
B
Buy 2/4/2021Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B- from C on 2/4/2021 due to an increase in the valuation index and total return index.
C
Hold 12/10/2020Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C from B on 12/10/2020 due to a decline in the volatility index, total return index and valuation index.
B
Buy 11/23/2020Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B from C on 11/23/2020 due to an increase in the growth index and valuation index. Total revenue increased 9.62% from $4.43B to $4.86B, and earnings per share increased from $0.6691 to $0.6944.
C
Hold 10/20/2020Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C from B on 10/20/2020 due to a large decline in the total return index, growth index and valuation index. EBIT declined 15.06% from $2.41B to $2.04B, total revenue declined 11.37% from $5B to $4.43B, and earnings per share declined from $0.7454 to $0.6691.
B
Buy 8/4/2020Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B from C on 8/4/2020 due to an increase in the volatility index and total return index.
C
Hold 7/17/2020Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C from B on 7/17/2020 due to a decline in the volatility index and valuation index.
B
Buy 6/8/2020Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B from C on 6/8/2020 due to an increase in the volatility index and valuation index.
C
Hold 5/29/2020Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C from B on 5/29/2020 due to a decline in the total return index and valuation index.
B
Buy 5/27/2020Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B from C on 5/27/2020 due to an increase in the volatility index.
C
Hold 5/22/2020Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C from B on 5/22/2020 due to a decline in the total return index, dividend index and solvency index. The quick ratio declined from 0.76 to 0.72.
B
Buy 2/24/2020Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B from C+ on 2/24/2020 due to a large increase in the total return index, dividend index and volatility index.
C
Hold 2/13/2020Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C+ from B- on 2/13/2020 due to a major decline in the growth index, valuation index and volatility index. Operating cash flow declined 69.22% from $2.49B to $765.5M, earnings per share declined from $0.6393 to $0.5478, and EBIT declined 8.59% from $1.93B to $1.76B.
B
Buy 11/27/2019Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B- from B on 11/27/2019 due to a decline in the volatility index.
B
Buy 11/12/2019Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B from B- on 11/12/2019 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 9.87% from $2.26B to $2.49B, and earnings per share increased from $0.6065 to $0.6393.
B
Buy 9/10/2019Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B- from C+ on 9/10/2019 due to an increase in the total return index, dividend index and volatility index.
C
Hold 5/24/2019Upgraded
Novo Nordisk A/S (NONOF) was upgraded to C+ from C on 5/24/2019 due to an increase in the volatility index and valuation index.
C
Hold 5/7/2019Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C from C+ on 5/7/2019 due to a decline in the dividend index, solvency index and valuation index. Debt to equity increased from 0.01 to 0.09, and the quick ratio declined from 0.79 to 0.65.
C
Hold 2/25/2019Upgraded
Novo Nordisk A/S (NONOF) was upgraded to C+ from C on 2/25/2019 due to an increase in the total return index, volatility index and dividend index.
C
Hold 10/30/2018Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C from C+ on 10/30/2018 due to a decline in the total return index and volatility index.
C
Hold 10/15/2018Upgraded
Novo Nordisk A/S (NONOF) was upgraded to C+ from C on 10/15/2018 due to an increase in the valuation index, total return index and dividend index.
C
Hold 9/25/2018Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C from C+ on 09/25/2018.
C
Hold 9/10/2018Upgraded
Novo Nordisk A/S (NONOF) was upgraded to C+ from C on 9/10/2018 due to a noticeable increase in the growth index, volatility index and valuation index. Operating cash flow increased 55.87% from $1.62B to $2.53B.
C
Hold 4/3/2018Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C from C+ on 4/3/2018 due to a decline in the total return index and volatility index.
C
Hold 2/9/2018Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C+ from B- on 2/9/2018 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 53.26% from $2.04B to $954.29M, earnings per share declined from $0.6258 to $0.5314, and EBIT declined 14.86% from $1.9B to $1.62B.
B
Buy 1/31/2018Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B- from C+ on 1/31/2018 due to a large increase in the total return index and volatility index.
C
Hold 10/23/2017Upgraded
Novo Nordisk A/S (NONOF) was upgraded to C+ from C on 10/23/2017 due to an increase in the total return index, dividend index and solvency index. The quick ratio increased from 0.82 to 0.96.
C
Hold 6/2/2017Upgraded
Novo Nordisk A/S (NONOF) was upgraded to C from C- on 6/2/2017 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from $0.5017 to $0.582, EBIT increased 14.68% from $1.69B to $1.93B, and operating cash flow increased 7.17% from $1.62B to $1.73B.
C
Hold 2/3/2017Upgraded
Novo Nordisk A/S (NONOF) was upgraded to C- from D+ on 2/3/2017 due to an increase in the dividend index and valuation index.
D
Sell 11/1/2016Downgrade
Novo Nordisk A/S (NONOF) was downgraded to D+ from C- on 11/1/2016 due to a noticeable decline in the growth index, total return index and solvency index. The quick ratio declined from 0.92 to 0.88, earnings per share declined from $0.5952 to $0.5804, and EBIT declined 1.83% from $1.9B to $1.86B.
C
Hold 9/22/2016Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C- from C on 9/22/2016 due to a noticeable decline in the total return index and dividend index.
C
Hold 3/11/2016Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C from B on 3/11/2016 due to a major decline in the volatility index, total return index and valuation index.
B
Buy 2/12/2016Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B from B- on 2/12/2016 due to an increase in the solvency index, dividend index and valuation index. The quick ratio increased from 0.99 to 1.03.
B
Buy 5/1/2015Downgrade
Novo Nordisk A/S (NONOF) was downgraded to B- from B on 5/1/2015 due to a decline in the dividend index and solvency index. The quick ratio declined from 1 to 0.74.
B
Buy 4/13/2015Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B from B- on 4/13/2015 due to a noticeable increase in the total return index.
B
Buy 2/6/2015Upgraded
Novo Nordisk A/S (NONOF) was upgraded to B- from C+ on 2/6/2015 due to an increase in the dividend index, growth index and volatility index. Total revenue increased 4.32% from $3.96B to $4.13B.
C
Hold 5/5/2014Downgrade
Novo Nordisk A/S (NONOF) was downgraded to C+ from B- on 5/5/2014 due to a decline in the total return index, solvency index and dividend index. The quick ratio declined from 1.23 to 0.88.
Weiss Ratings